Original ArticleIndian Journal of Pharmaceutical Education and ResearchVol. 55 | Issue 2 | 2021 | pp. 395–406Open access
Central Composite Design Aided Formulation Development and Optimization of Clarythromycin Extended-Release Tablets
- 1,
- 1,
- 1,
- 1,
- 1,
- 1,
- 1,
- 2,
- 1
- 1 Department of Industrial Pharmacy, Raghavendra Institute of Pharmaceutical Education and Research (RIPER)-Autonomous, KR Palli Cross, Chiyyedu, Anantapur, Andhra Pradesh, INDIA.
- 2 Department of Pharmacology, Raghavendra Institute of Pharmaceutical Education and Research (RIPER)-Autonomous, KR Palli Cross, Chiyyedu, Anantapur, Andhra Pradesh, INDIA.
Published in Indian Journal of Pharmaceutical Education and Research
Correspondence: Email: haranathriper@gmail.com
Copyright: © 2021 Manuscript Technomedia. This is an open access article.
- Published:
- Jan 1, 2021
- Received:
- Jul 2, 2020
- Accepted:
- Feb 9, 2021
- DOI:
- 10.5530/ijper.55.2.77
How to cite
Pharmacy, D. O. I., Education, R. I. O. P., (RIPER)-Autonomous, R., Cross, K. P., Chiyyedu, C., Anantapur, A., Pradesh, A., Pharmacology, I. D. O., & INDIA., I. (2021). Central Composite Design Aided Formulation Development and Optimization of Clarythromycin Extended-Release Tablets. Indian Journal of Pharmaceutical Education and Research, 55(2), 395–406. https://doi.org/10.5530/ijper.55.2.77
Abstract
Objectives: The present work was designed to formulate extended-release tablets of clarithromycin by means of central composite design. To assess the systematic considerate of input and output variables and to construct design space, the central composited design was used. Methods: The concentrations of tamarind kernel powder (X1), ethyl cellulose (X2) and polyvinyl pyrrolidone (X3) remained as independent variables and responses were drug release in 2 h, 8 h and t50%. Polynomial equations were employed to forecast the quantitative result of nondependent constraints at different levels on responses. The model stood nonlinear and the curvature outcome was significant. Henceforth the study employed central composite design for optimization. Wet granulation method was used to prepare the tablets and were evaluated for pharmacotechnical properties. Results: FTIR and DSC studies signposted that drug and excipients were compatible. Precompression constraints specified respectable flow properties. The in vitro drug release of entire formulations at the end of 12 h was found to be 96.14% - 98.23%. Increase in the concentration of tamarind kernel powder, ethyl cellulose decreased percentage drug release. Contour plots were utilized to assess the relationship between independent variables and dependent variables. Conclusion: The statistical model is scientifically effective as the investigational estimates and foreseen estimates proposed by the model were relatively close to each other. The outcomes confirmed the success of the anticipated design for development of clarithromycin extended-release tablets with optimized properties.
Keywords
Subject
Article metadata
| Title | Central Composite Design Aided Formulation Development and Optimization of Clarythromycin Extended-Release Tablets |
|---|---|
| Authors | Department of Industrial Pharmacy; Raghavendra Institute of Pharmaceutical Education; Research (RIPER)-Autonomous; KR Palli Cross; Chiyyedu Chiyyedu; Anantapur Anantapur; Andhra Pradesh; INDIA. Department of Pharmacology; INDIA. INDIA. |
| Affiliations | Department of Industrial Pharmacy, Raghavendra Institute of Pharmaceutical Education and Research (RIPER)-Autonomous, KR Palli Cross, Chiyyedu, Anantapur, Andhra Pradesh, INDIA.; Department of Pharmacology, Raghavendra Institute of Pharmaceutical Education and Research (RIPER)-Autonomous, KR Palli Cross, Chiyyedu, Anantapur, Andhra Pradesh, INDIA. |
| Corresponding author | haranathriper@gmail.com |
| Journal | Indian Journal of Pharmaceutical Education and Research |
| Volume / Issue | Vol. 55, Issue 2 (2021) |
Also in this issue
- Artificial Intelligence in Pharmacypp. 304–318
- Possible Insights into the Use of Silver Nanoparticles in Targeting SARS-CoV-2 (COVID-19)pp. 319–329
- An Overview of Dual Targeting Nanostructured Lipid Carriers for the Treatment of Ovarian Cancerpp. 330–335
- Overview of FBO Licensing in the India and New Dietary Ingredient Notification in the USpp. 336–345
- Targeted Drug Delivery System: Advantages, Carriers and Strategiespp. 346–353